TheraVida is dedicated to the development and commercialization of new therapies that improve the lives of patients, with fewer side effects, improved safety and efficacy, and better compliance
TheraVida, Inc., was founded in 2005 with the objective of improving patient care. There is a widely recognized need by patients, physicians, and regulatory agencies, for new medicines that are able to successfully treat disease with improved side effect and safety profiles. Our company is committed to this objective.
Using a unique and patent-protected combination drug technology, TheraVida is able to develop pharmaceutical products that have significantly better side effect and safety profiles, when compared with predecessor therapies. This same technology also has the potential to provide greater efficacy to patients.
TheraVida is a clinical stage company, with lead combination drug products in Phase II human studies for the treatment of overactive bladder and urinary incontinence. In addition to our focus on urology, the TheraVida combination drug technology has the potential to create improved therapies for various central nervous system disorders.
For more information about TheraVida, please contact us at:
951 Mariners Island Blvd., Suite 300
San Mateo, California, USA, 94404